BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 27349355)

  • 1. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
    Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
    J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological features and EGFR gene mutation status in elderly patients with resected non-small-cell lung cancer.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Ito H; Isaka T; Imai K; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Tsuboi M; Nakayama H; Masuda M
    BMC Cancer; 2014 Aug; 14():610. PubMed ID: 25152277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
    Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
    Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.
    Renaud S; Seitlinger J; Guerrera F; Reeb J; Beau-Faller M; Voegeli AC; Siat J; Clément-Duchêne C; Tiotiu A; Santelmo N; Costardi L; Ruffini E; Falcoz PE; Vignaud JM; Massard G
    Ann Surg Oncol; 2018 Apr; 25(4):1069-1078. PubMed ID: 29362963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
    Takamochi K; Oh S; Matsunaga T; Suzuki K
    J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor mutations are linked to skip N2 lymph node metastasis in resected non-small-cell lung cancer adenocarcinomas.
    Guerrera F; Renaud S; Tabbó F; Voegeli' AC; Filosso PL; Legrain M; Boita M; Schaeffer M; Beau-Faller M; Ruffini E; Falcoz PE; Inghirami G; Oliaro A; Massard G
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):680-688. PubMed ID: 28329143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
    Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
    Okamoto T; Kitahara H; Shimamatsu S; Katsura M; Takada K; Fujishita T; Suzuki Y; Morodomi Y; Tagawa T; Maehara Y
    Anticancer Res; 2016 Jun; 36(6):3057-63. PubMed ID: 27272827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
    Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
    Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique microRNAs in lung adenocarcinoma groups according to major TKI sensitive EGFR mutation status.
    Pak MG; Lee CH; Lee WJ; Shin DH; Roh MS
    Diagn Pathol; 2015 Jul; 10():99. PubMed ID: 26170125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
    Li X; Zhao C; Su C; Ren S; Chen X; Zhou C
    BMC Cancer; 2016 Oct; 16(1):828. PubMed ID: 27793199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Factors for Survival After Recurrence in Patients With Completely Resected Lung Adenocarcinoma: Important Roles of Epidermal Growth Factor Receptor Mutation Status and the Current Staging System.
    Kudo Y; Shimada Y; Saji H; Kato Y; Yoshida K; Matsubayashi J; Nagase S; Kakihana M; Kajiwara N; Ohira T; Nagao T; Ikeda N
    Clin Lung Cancer; 2015 Nov; 16(6):e213-21. PubMed ID: 25986624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
    Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
    J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas.
    Liu WS; Zhao LJ; Pang QS; Yuan ZY; Li B; Wang P
    Med Oncol; 2014 Jan; 31(1):771. PubMed ID: 24248816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas].
    Dong Y; Li Y; Peng H; Jin B; Huang A; Bai H; Xiong H; Han B
    Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):177-83. PubMed ID: 23601297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.